Immuneering Corp
IMRX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$3.73
KIRA · Stoqly’s AI analyst, in plain words
- Immuneering Corp lost $56.0M in fiscal 2025.
- Free cash flow was −$45.5M in fiscal 2025, — of revenue.
Market cap
$241M
P/E
—
Revenue
—
Net income
−$56.0M
Free cash flow
−$45.5M
Operating margin
—
Immuneering Corp in 30 seconds · fiscal 2025
Does it make a profit?
−$56.0M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Immuneering Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 6, 2026
- Legal name
- Immuneering Corp
- CIK
- 0001790340
Immuneering Corp · IMRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $2.1M | $0.3M | $0.0M | — | — |
| Revenue growth | −10.0% | −84.8% | −100.0% | — | — |
| Gross margin | 44.6% | 50.1% | — | — | — |
| Operating margin | −1,629.1% | −16,323.3% | — | — | — |
| Net income | −$33.5M | −$50.5M | −$53.5M | −$61.0M | −$56.0M |
| Net margin | −1,612.3% | −15,934.9% | — | — | — |
| Diluted EPS | −$2.46 | −$1.91 | −$1.88 | −$2.04 | −$1.27 |
| Cash | |||||
| Cash from operations | −$30.9M | −$44.1M | −$49.0M | −$55.0M | −$45.3M |
| Capital expenditure | $0.1M | $0.7M | $0.3M | $0.1M | $0.1M |
| Free cash flow | −$30.9M | −$44.8M | −$49.3M | −$55.1M | −$45.5M |
| FCF margin | −1,486.1% | −14,146.3% | — | — | — |
| Share count change | 175.0% | 93.8% | 7.7% | 5.5% | 46.8% |
| Debt and strength | |||||
| Cash and short-term investments | $149M | $106M | $85.7M | $36.1M | $129M |
| Shareholders' equity | $156M | $110M | $90.6M | $41.4M | $218M |
| Current ratio | 27.0x | 13.5x | 11.4x | 5.3x | 17.5x |
| Returns and quality | |||||
| Return on equity | −50.2% | −38.0% | −53.4% | −92.5% | −43.1% |
| Return on tangible equity | −22.5% | −49.2% | −64.0% | −177.7% | −26.5% |
| Piotroski F-score | 3 | 2 | 1 | — | — |
| Altman Z'' | 18.5 | 8.8 | 4.1 | −14.2 | 16.0 |
Insiders bought, 12 months
$0.3M
6 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Immuneering Corp · IMRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.73 a share, the company is worth $241M.
Source: SEC EDGAR XBRL filings (CIK 0001790340). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.